DU 6596
Latest Information Update: 27 Dec 2000
Price :
$50 *
At a glance
- Originator Daiichi Pharmaceutical
- Class Antineoplastics; Camptothecins; Small molecules
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 27 Dec 2000 Discontinued-Preclinical for Cancer in Japan (Unknown route)
- 30 Oct 1997 No-Development-Reported for Cancer in Japan (Unknown route)
- 13 Feb 1995 Preclinical development for Cancer in Japan (Unknown route)